Refine by MP, party, committee, province, or result type.
Industry committee Absolutely. In the document I sent to you, you will find a table that summarizes the governance and the accounting. Genome Canada has to make regular financial reports to the Government of Canada. The responsible department is Industry Canada. We do it in several ways. We submit
May 1st, 2008Committee meeting
Dr. Martin Godbout
Industry committee For Genome Canada, given that we invest in very few projects—less than 110 of them in eight years—the good news is that the projects are very large-scale. This has had a huge impact on the training and recruitment of post-doctoral students and principal researchers who have joine
May 1st, 2008Committee meeting
Dr. Martin Godbout
Industry committee Thank you, Mr. Vice-Chair and distinguished members of the Parliament of Canada. Genome Canada, a not-for-profit organization established in February 2000, was given the mandate by the Government of Canada to develop and implement a national strategy for supporting large-scale g
May 1st, 2008Committee meeting
Dr. Martin Godbout
Finance committee Yes, that is right.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee It is for a minimum of 10 years. We started in 2000. All my colleagues in the pharmaceutical and biopharmaceutical industry who are here know that it takes between 10 and 12 years before you can think about seeing a return on an investment. We have had some returns on investment
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee Welcome to Canada. You have Genome Canada, which is the main house, I would say, and you have six other genome centres across Canada, because there are differences in culture and differences in application. You won't do fisheries in Quebec, you'll do pharmaceuticals.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee As for the money, we asked for $380 million. We will raise $450 million on top of that, and the money will be distributed to all the regions.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee Based on excellence.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee Thank you, Mr. McCallum. Up until now, our government representatives seem to be saying that the intention is to support Genome Canada, but the issue is how to fund it? That depends on senior officials at the Department of Finance. As far as the brain gain is concerned, I can a
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee We have about 100 projects, and over 2,000 people are directly affected by the contributions of Genome Canada.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee To answer your question regarding $380 million requested, a strategic plan was prepared for Industry Canada and, upon request of the department, as is the case for any budget or grant application. The costs are assessed line by line, request by request. Right now, the financial
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee It's important from an economic standpoint. Let's say Genome Canada receives $1 from the federal government. We are then under obligation to obtain an equivalent sum from other sources. We receive $600 million over six years and we collected $840 million from other sources. Beli
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee Genome Canada has 17 employees. It's an investment fund.
October 25th, 2006Committee meeting
Dr. Martin Godbout
Finance committee Perfect. Thank you, Mr. Chairman. Good morning everybody. I am delighted to have the opportunity to meet with the members of the Standing Committee on Finance and to provide an overview of some of Genome Canada's most important accomplishments. Over the next few minutes, I wil
October 25th, 2006Committee meeting
Dr. Martin Godbout
Bill C-2 (39th Parliament, 1st Session) committee Absolutely. We do not have any problem with Bill C-2. Genome Canada has no problem with the government asking it for information. I would like to return to the issue of confidentiality. I believe this is not being approached in the proper way. For Genome Canada, the concept of c
May 30th, 2006Committee meeting
Dr. Martin Godbout